ArticleFrontiers in oncology2022
Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 16 citations in OpenAlex.
- Development of a decellularized extracellular matrix-derived wet adhesive for sustained drug delivery and enhanced wound healing.Materials today. Bio · 2025Article
- Analysis of Manifestations and Associated Factors of HIV-1 Associated Thrombocytopenia in a General Teaching Hospital in Western China.Infection and drug resistance · 2025Article
- Clinical laboratory analytes and platelet-associated parameters as surrogate markers of subclinical inflammation in latent tuberculosis infection.Frontiers in immunology · 2025Article
- Correlation analysis of peripheral platelet markers and disease phenotypes in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The postpartum uterine ultrasonographic scale in assessment of uterine involution after cesarean section in treated thrombophilia pregnant patients at term.Journal of clinical laboratory analysis · 2022Article
- Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myelodysplastic syndromes (MDSs) are a very heterogeneous group of myeloid disorders with high prevalence and risk of developing acute myeloid leukemia. The more accurate risk stratification can provide a better guidance of treatment. The platelet-large cell ratio (P-LCR) is a parameter reported in complete blood cell count tests, and was associated with many diseases, but its role in MDS is not clear. Purpose: This study aims to explore the impact of the P-LCR on the prognosis of patients with MDS, which is of great significance for clinical treatment. Methods: In the retrospective study, 122 newly diagnosed MDS patients were enrolled. We used the bioinformatics tool X-tile to define a P-LCR threshold of 36.7% to predict prognosis. Patients were divided into P-LCR Results: Results show that the P-LCR Conclusion: This study is the first report showing that the P-LCR would be a simple and immediately available biomarker for predicting the prognosis of MDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.